| Reaction Details |
|---|
 | Report a problem with these data |
| Target | 5-hydroxytryptamine receptor 2B |
|---|
| Ligand | BDBM21395 |
|---|
| Substrate/Competitor | n/a |
|---|
| Ki | 3240±n/a nM |
|---|
| Comments | PDSP_1014 |
|---|
| Citation |  Wainscott, DB; Lucaites, VL; Kursar, JD; Baez, M; Nelson, DL Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences. J Pharmacol Exp Ther276:720-7 (1996) [PubMed] |
|---|
| More Info.: | Get all data from this article |
|---|
| |
| 5-hydroxytryptamine receptor 2B |
|---|
| Name: | 5-hydroxytryptamine receptor 2B |
|---|
| Synonyms: | 5-HT2B | 5-hydroxytryptamine receptor 2B | 5HT2B_RAT | Htr2b | Serotonin 2b (5-HT2b) receptor | Serotonin receptor 2a and 2b (5HT2A and 5HT2B) | Srl |
|---|
| Type: | Enzyme Catalytic Domain |
|---|
| Mol. Mass.: | 53668.47 |
|---|
| Organism: | RAT |
|---|
| Description: | 5-HT2B HTR2B RAT::P30994 |
|---|
| Residue: | 479 |
|---|
| Sequence: | MASSYKMSEQSTISEHILQKTCDHLILTDRSGLKAESAAEEMKQTAENQGNTVHWAALLI
FAVIIPTIGGNILVILAVSLEKRLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEATW
PLPLALCPAWLFLDVLFSTASIMHLCAISLDRYIAIKKPIQANQCNSRTTAFVKITVVWL
ISIGIAIPVPIKGIEADVVNAHNITCELTKDRFGSFMLFGSLAAFFAPLTIMIVTYFLTI
HALRKKAYLVRNRPPQRLTRWTVSTVLQREDSSFSSPEKMVMLDGSHKDKILPNSTDETL
MRRMSSAGKKPAQTISNEQRASKVLGIVFLFFLLMWCPFFITNVTLALCDSCNQTTLKTL
LQIFVWVGYVSSGVNPLIYTLFNKTFREAFGRYITCNYQATKSVKVLRKCSSTLYFGNSM
VENSKFFTKHGIRNGINPAMYQSPVRLRSSTIQSSSIILLNTFLTENDGDKVEDQVSYI
|
|
|
|---|
| BDBM21395 |
|---|
| n/a |
|---|
| Name | BDBM21395 |
|---|
| Synonyms: | 3-(2-(4-(4-Fluorobenzoyl)piperidinol)ethyl)-2,4(1H,3H)-quinazolinedione | 3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)-1,2,3,4-tetrahydroquinazoline-2,4-dione | CHEMBL1628637 | CHEMBL51 | Ketanserin | R-41,468 | R-41-468 | R41,468 | [3H]-Ketanserin |
|---|
| Type | radiolabeled ligand |
|---|
| Emp. Form. | C22H22FN3O3 |
|---|
| Mol. Mass. | 395.4268 |
|---|
| SMILES | Fc1ccc(cc1)C(=O)C1CCN(CCn2c(=O)[nH]c3ccccc3c2=O)CC1 |
|---|
| Structure | 
|
|---|
Search and Browse
